LP
ESPR

LMR Partners’s Esperion Therapeutics ESPR Stock Holding History

LMR Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,400
Closed -$17.2K – 966
2023
Q2 		$17.2K Buy
+12,400
New +$17.3K ﹤0.01% 738

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

LMR Partners's ESPR Position: Q2 2026 in Review

LMR Partners increased its Esperion Therapeutics (ESPR) stake by 4,382% in Q2 2026, buying an estimated $4.4M and bringing the position to 1,607,177 shares worth $5.08M. The position accounts for 0.02% of the portfolio, ranked #648.

LMR Partners first reported a position in ESPR in Q1 2023 and has held it in 5 quarters since. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • LMR Partners held 1,607,177 shares of Esperion Therapeutics worth $5.08M as of Q2 2026.
  • LMR Partners bought 1,571,318 Esperion Therapeutics shares in Q2 2026, an estimated $4.4M.
  • Esperion Therapeutics made up 0.02% of LMR Partners's portfolio in Q2 2026, its #648 holding.
  • LMR Partners first reported a position in Esperion Therapeutics in Q1 2023 and has held it in 5 quarters since.
  • 192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.